NASDAQ:EIGR Eiger BioPharmaceuticals (EIGR) Stock Price, News & Analysis → A ‘DeFi Summer’ Projected! (From Crypto 101 Media) (Ad) Free EIGR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range N/A50-Day Range$1.30▼$7.1752-Week Range N/AVolume137,800 shsAverage Volume103,866 shsMarket Capitalization$2.55 millionP/E RatioN/ADividend YieldN/APrice Target$120.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get Eiger BioPharmaceuticals alerts: Email Address Eiger BioPharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside∞ Upside$120.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-1.65Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.53 out of 5 stars 3.5 Analyst's Opinion Consensus RatingEiger BioPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageEiger BioPharmaceuticals has received no research coverage in the past 90 days.Read more about Eiger BioPharmaceuticals' stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for EIGR. Previous Next 0.0 Dividend Strength Dividend YieldEiger BioPharmaceuticals does not currently pay a dividend.Dividend GrowthEiger BioPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreEiger BioPharmaceuticals has received a 61.42% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Lonafarnib" and "Clinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Eiger BioPharmaceuticals is -1.65. Previous Next 0.0 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 1 news article for Eiger BioPharmaceuticals this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for EIGR on MarketBeat in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Eiger BioPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.22% of the stock of Eiger BioPharmaceuticals is held by insiders.Percentage Held by Institutions62.46% of the stock of Eiger BioPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Eiger BioPharmaceuticals' insider trading history. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Eiger BioPharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Eiger BioPharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyWhat’s Really Next for America…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. About Eiger BioPharmaceuticals Stock (NASDAQ:EIGR)Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to treat hepatitis delta virus infection. The company's product candidate also include Lambda, which targets type III interferon receptors that has completed Phase II clinical trials; Lonafarnib for the treatment of progeria and progeroid laminopathies; and Avexitide for the treatment of congenital hyperinsulinism, as well as has completed Phase II clinical trials to treat post-bariatric hypoglycemia. Eiger BioPharmaceuticals, Inc. was founded in 2008 and is headquartered in Palo Alto, California.Read More Ad Porter & CompanyWhat’s Really Next for America…Millions of Unsuspecting Americans Could be Wiped Out… Yet those who watch this bombshell exposé and prepare before it’s too late could have the chance to protect their financial future and grow their wealth significantly.Click here to stream this controversial exposé now. EIGR Stock News HeadlinesMay 10, 2024 | americanbankingnews.comStockNews.com Begins Coverage on Eiger BioPharmaceuticals (NASDAQ:EIGR)May 1, 2024 | wsj.comFirm Retention Summary: Eiger BioPharmaceuticalsApril 8, 2024 | wsj.comRequiem for Eiger BiopharmaceuticalsApril 2, 2024 | bizjournals.comPeninsula biotech files for Chapter 11 bankruptcy protectionApril 1, 2024 | wsj.comEiger BioPharmaceuticals Files for BankruptcyApril 1, 2024 | marketwatch.comHealthcare stocks fade as obesity-drug optimism fadesApril 1, 2024 | msn.comMetabolic Diseases-Focused Eiger BioPharmaceuticals Files For Bankruptcy, Stock NosedivesApril 1, 2024 | finance.yahoo.comEiger Biopharmaceuticals Files for Chapter 11 BankruptcyApril 1, 2024 | msn.comEiger reportedly files for Chapter 11, stock plunges 52%April 1, 2024 | globenewswire.comEiger BioPharmaceuticals Files for Voluntary Chapter 11 ProtectionMarch 20, 2024 | seekingalpha.comEIGR Eiger BioPharmaceuticals, Inc.February 8, 2024 | bizjournals.comNew Natomas industrial property owner Eiger Capital could be buying more local assetsFebruary 4, 2024 | bizjournals.comPanattoni sells part of Natomas Advanced Logistics Center to Eiger CapitalJanuary 18, 2024 | finance.yahoo.comEiger and Partner, AnGes, Receive Approval for Zokinvy® (lonafarnib) for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in JapanJanuary 4, 2024 | msn.comEiger BioPharmaceuticals announces 1-for-30 reverse stock splitJanuary 4, 2024 | finance.yahoo.comEiger BioPharmaceuticals, Inc. Announces 1-for-30 Reverse Stock SplitDecember 7, 2023 | yahoo.com‘Bob Eiger’ Trends on X After Elon Musk Blasts the Disney CEO With Multi-Tweet TypoDecember 4, 2023 | finance.yahoo.comEiger BioPharmaceuticals Insiders US$2.1m Short Of Breakeven On Stock PurchaseNovember 11, 2023 | finanznachrichten.deEiger BioPharmaceuticals, Inc.: Eiger BioPharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business UpdateSeptember 15, 2023 | markets.businessinsider.comAnalysts Are Bullish on These Healthcare Stocks: Ocular Therapeutix (OCUL), Eiger Biopharmaceuticals (EIGR)September 13, 2023 | marketwatch.comEiger BioPharmaceuticals Shares Hit New Lows After Scrapped Hepatitis D StudySeptember 13, 2023 | markets.businessinsider.comEiger To Discontinue Peginterferon Lambda Trial In CHD Patients; Stock Down In PremarketSeptember 13, 2023 | msn.comWhy Is Hepatitis Player Eiger BioPharma Stock Trading Lower Today?September 13, 2023 | investorplace.comWhy Is Eiger BioPharmaceuticals (EIGR) Stock Down 31% Today?September 13, 2023 | reuters.comEiger to discontinue late-stage hepatitis drug study over safety concernsSee More Headlines Receive EIGR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Eiger BioPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/04/2021Today5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolNASDAQ:EIGR CUSIPN/A CIK1305253 Webwww.eigerbio.com Phone(650) 272-6138Fax650-618-1621Employees56Year FoundedN/APrice Target and Rating Average Stock Price Target$120.00 High Stock Price Target$150.00 Low Stock Price Target$90.00 Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($59.1592) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-96,780,000.00 Net Margins-590.80% Pretax Margin-590.79% Return on Equity-332.49% Return on Assets-99.77% Debt Debt-to-Equity RatioN/A Current Ratio3.31 Quick Ratio3.24 Sales & Book Value Annual Sales$15.77 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value$37.68 per share Price / BookN/AMiscellaneous Outstanding Shares1,480,000Free Float1,419,000Market Cap$2.55 million OptionableOptionable Beta1.83 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. David Apelian M.B.A. (Age 59)M.D., Ph.D., CEO & Director Comp: $204.39kDr. Jeffrey S. Glenn M.D. (Age 61)Ph.D., Scientific Founder & Independent Director Comp: $67kMr. William G. Kaichoff CPA (Age 58)CFO and Principal Financial & Accounting Officer Mr. Christopher A. Kurtz (Age 57)Chief Technical Officer Mr. James Vollins J.D. (Age 55)General Counsel, Chief Compliance Officer & Corporate Secretary Dr. Colin Hislop M.D. (Age 66)MBBS, Senior Vice President of Clinical & Development Operations Dr. Colleen Craig M.D.Senior Vice President of Metabolic DiseasesMore ExecutivesKey Competitors9 Meters BiopharmaNASDAQ:NMTR60 Degrees PharmaceuticalsNASDAQ:SXTPInnovative EyewearNASDAQ:LUCYAgile TherapeuticsNASDAQ:AGRXOnconetixNASDAQ:ONCOView All CompetitorsInsiders & InstitutionsPropel Bio Management LLCSold 4,245,051 shares on 5/14/2024Ownership: 9.891%Richard A KayneBought 779 shares on 11/2/2023Total: $7,011.00 ($9.00/share)Richard A KayneBought 5,161 shares on 10/31/2023Total: $37,159.20 ($7.20/share)View All Insider TransactionsView All Institutional Transactions EIGR Stock Analysis - Frequently Asked Questions Should I buy or sell Eiger BioPharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eiger BioPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EIGR shares. View EIGR analyst ratings or view top-rated stocks. What is Eiger BioPharmaceuticals' stock price target for 2024? 2 Wall Street research analysts have issued 12-month price targets for Eiger BioPharmaceuticals' shares. Their EIGR share price targets range from $90.00 to $150.00. On average, they predict the company's stock price to reach $120.00 in the next year. View analysts price targets for EIGR or view top-rated stocks among Wall Street analysts. How were Eiger BioPharmaceuticals' earnings last quarter? Eiger BioPharmaceuticals, Inc. (NASDAQ:EIGR) posted its earnings results on Thursday, November, 4th. The biotechnology company reported ($19.50) EPS for the quarter, missing analysts' consensus estimates of ($17.40) by $2.10. The biotechnology company had revenue of $3.04 million for the quarter, compared to analyst estimates of $2.54 million. Eiger BioPharmaceuticals had a negative trailing twelve-month return on equity of 332.49% and a negative net margin of 590.80%. During the same period in the previous year, the business earned ($15.60) earnings per share. When did Eiger BioPharmaceuticals' stock split? Eiger BioPharmaceuticals shares reverse split on Monday, January 8th 2024. The 1-30 reverse split was announced on Monday, January 8th 2024. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 8th 2024. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split. What other stocks do shareholders of Eiger BioPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Eiger BioPharmaceuticals investors own include Achillion Pharmaceuticals (ACHN), Gilead Sciences (GILD), Skyworks Solutions (SWKS), ZIOPHARM Oncology (ZIOP), Amarin (AMRN), Celldex Therapeutics (CLDX), Catalyst Pharmaceuticals (CPRX), Exelixis (EXEL), SCYNEXIS (SCYX) and Sangamo Therapeutics (SGMO). Who are Eiger BioPharmaceuticals' major shareholders? Eiger BioPharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Propel Bio Management LLC (9.89%). Insiders that own company stock include David Apelian, Eldon C Mayer III, Richard A Kayne, Sriram Ryali and Thomas John Dietz. View institutional ownership trends. This page (NASDAQ:EIGR) was last updated on 5/17/2024 by MarketBeat.com Staff From Our Partners348 million Americans lives to END as we know it?The Oxford ClubCrypto Pioneer Says: “The last crypto bull market has begun.”InvestorPlaceInvest in the "Trojan Horse" of Alzheimer's TreatmentBehind the MarketsHow Biden has already won 2024Porter & CompanyA once-in-a-century investment opportunityStansberry ResearchCharles Payne Demystifies OptionsUnstoppable ProsperityBiden FINISHED On June 13th?Paradigm PressWhy Is Gold On a MASSIVE rally? Huge Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eiger BioPharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
